EcoDrugPlus

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSMMDG00005017955
Gene Symbol: CYP19A1
3 Cross references
244 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSMMDG00005002051
Gene Symbol: CYP3A65
1 Cross references
474 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSMMDG00005007668
Gene Symbol: LOC115367814
3 Cross references
192 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSMMDG00005001265
Gene Symbol: LOC115374925
3 Cross references
197 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSMMDG00005011622
Gene Symbol: LOC115361964
3 Cross references
189 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSMMDG00005018237
Gene Symbol: LOC115372913
3 Cross references
214 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSMMDG00005002759
Gene Symbol: DGAT1A
1 Cross references
190 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSMMDG00005022154
Gene Symbol: DGAT1B
1 Cross references
189 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSMMDG00005006943
Gene Symbol: DHODH
3 Cross references
172 Possible Orthologues:

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSMMDG00005022666
Gene Symbol: DPYDB
1 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSMMDG00005008427
Gene Symbol: DDR2
1 Cross references
204 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSMMDG00005013259
Gene Symbol: DDR2
1 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).